Embed Size (px)
Citation preview
BIOCON is a fully-integrated, innovation-led global biopharmaceutical
company committed to enhance affordable access to complex therapies for
chronic conditions like diabetes, cancer and autoimmune. It has developed
and taken differentiated Small Molecules, Novel Biologics and a range of
Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh-Insulin and Insulin
Glargine) from 'Lab to Market' in India, key emerging and developed
markets. It has a large portfolio of biosimilars under clinical development with
three of these approved in developed markets of US, EU, Japan and
Australia. Its Novel pipeline includes promising assets like Insulin Tregopil,
anti-CD6 antibody and a fusion protein for immuno-oncology. Some of its key
® ®brands are INSUGEN (rh-insulin), Basalog One (prefilled Glargine pen),
® ®CANMAb™ (Trastuzumab), KRABEVA (Bevacizumab), BIOMAb-EGFR
(Nimotuzumab) and ALZUMAb™ (Itolizumab).
Biocon:�Enhancing�Global�Healthcare
About:
• ~1,400 Patents Filed Globally
• ~1,150 Patents Granted
• ~690 Trademarks Registered
• 9 Biologics taken from 'Lab to Market': 2 Novels & 7 Biosimilars
• ~120 Countries where our Products are Available
• 25+ cGMP Approvals from International Regulatory Agencies*
® ®• Key Brands: INSUGEN (rh-insulin), Basalog One (prefilled Glargine pen), ® ®
CANMAb™ (Trastuzumab), KRABEVA (Bevacizumab), BIOMAb-EGFR
(Nimotuzumab) and ALZUMAb™ (Itolizumab), GCC etc.
To enhance
global
healthcare
through
innovative and
affordable
biopharma
products for
patients,
partners and
healthcare
systems
across the
globe.
Vision
A Credible Biopharma Enterprise:
Fact�Sheet�
*As of 31 March 2018
• First listed 'pure play' biopharmaceuticals
company in India.
• First to launch an indigenously developed
novel biologic in India.
• First company from India to have a
biosimilar commercialized in the U.S.
• First company from India to have a
biosimilar commercialized in Japan.
• First novel anti-CD6 monoclonal antibody
developed and launched anywhere in the
world by Biocon.
• Largest statins producer; Biocon's drug
substances are used to produce '1 in
every 3' statin pills globally.
Biocon at a Glance :
Bangalore | Malaysia | Hyderabad | Visakhapatnam
Manufacturing Locations
• Largest biologics manufacturing capacity
in India.
• Largest insulins manufacturing complex in
Asia set up by Biocon in Malaysia.
• Largest integrated biotech hub, 90- acre
Biocon Park, located in Bangalore.
• Among Top 3 biosimilar players globally
for rh-Insulin & Insulin Glargine in terms of
volume market share.
• Among Top 10 Global Biotech Employers
by prestigious US-based Science
magazine.
• Wide presence with marketing footprint
across 120 countries.
68%
32%
International Domestic
Revenue: Geographic Distribution
Revenue:Business Mix*
33%
17%14%
31%
5%
Small MoleculesBiologics
Branded FormulationsResearch Services
Other Income
*Includes inter-segment revenue
Revenue: Rs 43,359 million#
#as of March 31, 2018
10,293
Global Employee BaseNo. of Employees: 10,000+#
#as of March 31, 2018
6,149
4,144
Biocon Syngene
GROWTHVERTICALS
For more information contact:
Issued by Corporate Communications | Email: [email protected] | www.biocon.com
Seema Ahuja
VP & Global Head of Communications
T: +91-80-2808-2222
Email: [email protected]
Growth Verticals: Aligned with Shifting Paradigms
BIOLOGICSNovel Biologics & Biosimilars
(rh-insulin, Insulin Analogs, Monoclonal Antibodies & Recombinant Proteins)
Differentiated APIs & Generic Formulations
SMALL MOLECULES
Finished Dosage Business in India
& Overseas
BRANDED FORMULATIONS
Syngene(Molecular Biology, Biologics, Synthetic
Chemistry, Bioinformatics & Clinical Research)
RESEARCH SERVICES
